Image

CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study

CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.

Description

The Atrium Health cardiac rehabilitation program delivers a comprehensive approach to improve cardiac performance including supervised exercise programs and has the ideal infrastructure to offer cardio-oncology rehabilitation (CORE) to all our cancer patients in the future. Currently neither CORE nor cardiac rehabilitation for HFpEF are covered by insurance, and hence the targeting of a higher risk cancer and non-cancer population of cardiac amyloidosis patients to objectively measure the benefits of a supervised exercise program ultimately to expand eligibility to all cancer patients and shape the treatment and payor landscape in the future.

Eligibility

Inclusion Criteria:

  • Age > 18
  • New York Heart Association (NYHA) Class I-III Heart Failure
  • Able to Exercise
  • On stable treatment for their cardiac amyloidosis or under active surveillance
  • Life expectancy of at least 6 months
  • Ability to understand and the willingness to sign a written informed consent document in English, and the willingness/ability to comply with the protocol activities
  • Participant must be able and willing to follow the cardiac rehabilitation activities

Exclusion Criteria:

  • Inability to provide informed consent
  • Inability to commit to in-person supervised exercise sessions for three one-hour sessions a week for 12 weeks
  • NYHA Class IV Heart Failure
  • Pulmonary disease requiring home oxygen
  • Gait instability or history of prior falls
  • In the opinion of the Principal Investigator, have a clinically significant comorbid disease that is likely to affect the ability of the patient to complete the trial, interfere with their ability with measurement of self-reported outcomes.

Study details
    Cardiac Amyloidosis

NCT06096675

Wake Forest University Health Sciences

18 February 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.